

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) July 28, 2006

BECTON, DICKINSON AND COMPANY

(Exact Name of Registrant as Specified in Its Charter)

New Jersey

(State or Other Jurisdiction of Incorporation)

001-4802

22-0760120

(Commission File Number)

(IRS Employer Identification No.)

1 Becton Drive, Franklin Lakes, New Jersey

07417-1880

(Address of Principal Executive Offices)

(Zip Code)

(201) 847-6800

(Registrant's Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K Filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

On July 28, 2006, Becton, Dickinson and Company ("BD") issued a press release announcing its financial results for the third fiscal quarter of fiscal year 2006. A copy of the press release is furnished as Exhibit 99.1 to this report.

The press release furnished as Exhibit 99.1 contains certain financial measures that differ from those presented in accordance with U.S. generally accepted principles (GAAP), as follows:

- Revenues. We present revenue growth rates at constant foreign exchange rates. We believe that presenting growth rates at constant foreign exchange rates allows investors to view the underlying operating results of BD and of its segments without the impact of fluctuations in foreign currency exchange rates, thereby facilitating comparisons to prior periods.
- Selling and Administrative Expense. We present selling and administrative expense, both alone and as a percentage of revenues, after excluding the impact of insurance settlements occurring during the period presented. As these settlements are not part of ordinary operations, management believes that these adjusted measures are more indicative of BD's underlying performance. Management also presents these adjusted measures in order to assist investors in comparing BD's selling and administrative expense for the period to prior periods.
- Research and Development Expense. We present research and development expense, both alone and as a percentage of revenues, after excluding the impact of the in-process research and development charge relating to the acquisition of GeneOhm Sciences Inc. ("GeneOhm"). As this non-cash charge is not part of ordinary operations and serves to increase research and development expense for the period, management believes that these adjusted measures are more indicative of BD's underlying performance. Management also presents these adjusted measures in order to assist investors in comparing BD's research and development expense for the period to prior periods.
- Operating Income. We present BD's operating income, both alone and as a percentage of revenues, after excluding the impact of insurance settlements and the in-process research and development charge relating to the GeneOhm acquisition. Management believes that these adjusted measures of operating income are more indicative of BD's underlying performance, and also allow investors to better understand BD's comparative operating performance for the period presented.
- Income Taxes/Effective Tax Rate. We present income taxes and effective tax rate after excluding the impact of insurance settlements. Since these items are not part of ordinary operations, management believes these adjusted measures are more indicative of BD's underlying performance and facilitate comparisons to prior periods.

We also present income taxes and effective tax rate for the prior year periods after excluding the effects of significant reversals of tax reserves and/or the effects of changes in tax laws and regulations and other events that caused the tax rate for the period presented to vary from BD's then expected effective tax rate for the full year. Significant reversals of tax reserves and the items mentioned above that effect our periodic effective tax rate cause fluctuations in BD's income from continuing operations from period to period that management believes are unrelated to BD's underlying operating performance. Accordingly, management believes that providing the impact of such effects allows investors to better understand BD's comparative operating performance for the periods presented.

- Income from Continuing Operations. We present operating income from continuing operations, both alone and as a percentage of revenues, after excluding the impact of insurance settlements and the in-process research and development charge relating to the GeneOhm acquisition. Since these items are not part of ordinary operations, management believes that these adjusted measures are more indicative of BD's underlying performance and also allow investors to better understand BD's comparative operating performance for the period presented.

We also present income from operations for the prior year periods after excluding the effects of significant reversals of tax reserves and/or the effects of changes in tax laws and regulations and other events that caused the tax rate for the period presented to vary from BD's then expected effective tax rate for the full year. For the reasons discussed above, management believes that providing the impact of such effects allows investors to better understand BD's comparative operating performance for the periods presented.

- Earnings Per Share. We present earnings per share from continuing operations, both for the periods presented and on a prospective basis, after excluding the impact of insurance settlements and the in-process research and development charge relating to the GeneOhm acquisition. Since these items are not part of ordinary operations, management believes that these adjusted measures of earnings per share from continuing operations are more indicative of BD's underlying performance and also allow investors to better understand BD's comparative operating performance for the periods presented.

We also present earnings per share from continuing operations for prior periods after excluding (i) the effects of significant reversals of tax reserves, (ii) the effects of changes in tax laws and regulations and other events that caused the tax rate during the period to vary from BD's expected effective tax rate for the full year, and/or (iii) the impact on taxes of the planned repatriation of foreign earnings under the provisions of the American Jobs Creation Act. These items cause fluctuations in BD's operating results that management believes are unrelated to BD's underlying operating performance. Accordingly, management believes that providing the impact of such items allows investors to better understand BD's comparative operating performance for the periods presented.

BD's management uses each of these non-GAAP measures in its own evaluation of BD's performance, particularly when comparing performance to past periods. Management also uses the non-GAAP results for budget planning purposes on a quarterly and annual basis.

Non-GAAP results should not be considered in isolation and are not in accordance with, or a substitute for, GAAP results. Our non-GAAP results may differ from similar measures used by other companies, even if similar terms are used to identify such measures. Although BD's management believes non-GAAP results are useful in evaluating the performance of its business, its reliance on these measures is limited since items excluded from such measures may have a material impact on BD's net income, earnings per share or cash flows calculated in accordance with GAAP. Therefore, management typically uses non-GAAP results in conjunction with GAAP results to address these limitations. Investors should also consider these limitations when evaluating BD's results.

BD provides non-GAAP measures to investors on a supplemental basis, as they provide additional insight into BD's financial results. Management believes the non-GAAP results provide a reasonable measure of BD's underlying performance before the effects of items that are considered by management to be outside of BD's underlying operational results or that affect period to period comparability.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

Exhibits. — Exhibit 99.1 Press release dated July 28, 2006, which is furnished pursuant to Item 2.02.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BECTON, DICKINSON AND COMPANY
(Registrant)

By: /s/ Dean J. Paranicas
Dean J. Paranicas
Vice President, Corporate
Secretary and Public Policy

Date: July 28, 2006

INDEX TO EXHIBITS

**Exhibit
Number**

Description of Exhibits

99.1

Press release dated July 28, 2006, which is furnished pursuant to Item 2.02.

News Release



Contact:

Patricia A. Spinella, Investor Relations – 201-847-5453
Colleen T. White, Corporate Communications – 201-847-5369

BD ANNOUNCES RESULTS FOR THIRD FISCAL QUARTER
Reports record revenues; raises earnings guidance for full fiscal year

Franklin Lakes, NJ (July 28, 2006)– BD (Becton, Dickinson and Company) (NYSE: BDX) today reported record quarterly revenues of \$1.484 billion for the third fiscal quarter ended June 30, 2006, representing an increase of 7 percent over the prior year period. This quarter’s growth rate reflects an overall estimated 1 percent unfavorable impact from foreign currency translation, which affected all segments.

“Our continued strong performance this quarter indicates that the strategy we are implementing is succeeding,” said Edward J. Ludwig, Chairman, President and Chief Executive Officer. “Strong operating performance is enabling us to make investments such as the acquisition of GeneOhm, which is performing as expected and is a key component of our strategy to reduce healthcare-associated infections. We’re also increasing the pace of our R&D spending to fuel growth through innovation. Additionally, I’m very pleased to announce that, once again, we’re raising earnings guidance for fiscal 2006.”

Analysis of Third Quarter and Nine-month Period of Fiscal Year 2006 and 2005 Earnings

The following analysis of diluted earnings per share from continuing operations for the third quarter and nine-month period of fiscal 2006 and 2005 identifies specified items that affect the comparability of results between periods.

(Table 1)

	Three Months Ended June 30,			Nine Months Ended June 30,		
	FY2006	FY2005	% Incr.	FY2006	FY2005	% Incr.
Diluted EPS from Continuing Operations: ⁽¹⁾	\$ 0.81	\$ 0.73	11%	\$ 2.26	\$ 2.18	4%
Specified Items:						
Insurance Settlements ⁽²⁾	—	—		(0.04)	—	
In-Process Research and Development Charge ⁽³⁾	—	—		0.21	—	
Tax Examinations ⁽⁴⁾	—	—		—	(0.04)	
Tax Rate Impact ⁽⁵⁾	—	0.01		—	(0.02)	
	—	0.01		0.17	(0.06)	
Diluted EPS from Continuing Operations Excluding Specified Items: ⁽¹⁾	\$ 0.81	\$ 0.74	9%	\$ 2.43	\$ 2.12	15%

(1) Includes the effect on diluted earnings per share from continuing operations of a 2 cent reduction in the third quarter and a 3 cent reduction in the nine-month period ended June 30, 2006 relating to GeneOhm operations, which were acquired in February 2006.

(2) Represents the effect on diluted earnings per share from continuing operations related to proceeds received from insurance settlements regarding the Company's previously owned latex glove business.

(3) Represents the effect on diluted earnings per share from continuing operations of the in-process research and development charge recorded in the second quarter of fiscal 2006 related to the GeneOhm acquisition.

(4) Represents the effect on diluted earnings per share from continuing operations of the reversal of tax reserves in the first fiscal quarter of 2005 in connection with the conclusion of tax examinations in four non-U.S. jurisdictions.

(5) Represents the effect on diluted earnings per share from continuing operations of tax-related events that caused the quarterly tax rate to vary from the then-expected effective tax rate for fiscal year 2005.

As illustrated in Table 1, diluted earnings per share from continuing operations of 81 cents for the third fiscal quarter of 2006 increased by 9 percent over diluted earnings per share from continuing operations, excluding specified items, of 74 cents for the third fiscal quarter of 2005. For the nine-month period, diluted earnings per share from continuing operations, excluding specified items, of \$2.43 for fiscal 2006 increased by 15 percent over diluted earnings per share from continuing operations, excluding specified items, of \$2.12 for fiscal 2005.

Segment Results

In the BD Medical segment, worldwide revenues for the quarter were \$828 million, representing an increase of 8 percent from the prior year period. Strong sales in the Diabetes Care unit contributed to growth. U.S. sales of safety-engineered products totaled \$132 million compared with \$119 million in the prior year's quarter. For the nine-month period ended June 30, 2006, U.S. sales of safety-engineered products totaled \$387 million compared with \$360 million in the prior year's period. Included in BD Medical revenues were international sales of safety-engineered products of \$24 million compared with \$22 million in the prior year's quarter. For the nine-month period ended June 30, 2006, international sales of safety-engineered products totaled \$68 million compared with \$60 million in the prior year's period. For the nine-month period ended June 30, 2006, the BD Medical segment reported 9 percent revenue growth over the prior year period.

In the BD Diagnostics segment, worldwide revenues for the quarter were \$436 million, representing an increase of 6 percent from the prior year period. The Diagnostic Systems unit of the segment reported revenue growth of 5 percent. The Preanalytical Systems unit of the segment reported revenue growth of 7 percent. U.S. sales of safety-engineered products totaled \$102 million compared with \$92 million in the prior year's quarter. For the nine-month period ended June 30, 2006, U.S. sales of safety-engineered products totaled \$295 million compared with \$258 million in the prior year's period. Included in Preanalytical Systems revenues were international sales of safety-engineered products of

\$60 million, compared with \$52 million in the prior year's quarter. For the nine-month period ended June 30, 2005, international sales of safety-engineered products totaled \$167 million compared with \$143 million in the prior year's period. For the nine-month period ended June 30, 2006, the BD Diagnostics segment reported 5 percent revenue growth over the prior year period.

In the BD Biosciences segment, worldwide revenues from continuing operations for the quarter were \$219 million, representing an increase of 9 percent from the prior year period. Sales of flow cytometry instruments and reagents as well as cell imaging products contributed to sales growth. For the nine-month period ended June 30, 2006, the BD Biosciences segment reported 9 percent revenue growth over the prior year period.

Geographic Results

Third quarter revenues in the U.S. were \$719 million, representing an increase of 11 percent over the prior year period. Revenues outside the U.S. were \$765 million, representing an increase of 5 percent over the prior year period, and reflected an estimated 1 percent unfavorable impact from foreign currency translation.

For the nine-month period ended June 30, 2006, revenues in the U.S. were \$2.102 billion, representing an increase of 10 percent over the prior year period. Revenues outside of the U.S. were \$2.246 billion, representing an increase of 5 percent over the prior year period, and reflected an estimated 3 percent unfavorable impact from foreign currency translation.

Fiscal 2006 Outlook for Fourth Quarter and Full Year

The following analysis of estimated diluted earnings per share from continuing operations for the fourth fiscal quarter and full fiscal year identifies specified items that affect the comparability of results between periods.

(Table 2)

	Three Months Ended September 30,			Twelve Months Ended September 30,		
	FY2006	FY2005	% Incr.	FY2006	FY2005	% Incr.
	(Estimated)			(Estimated)		
Diluted EPS from Continuing Operations:⁽¹⁾	\$ 0.83-\$0.84	\$ 0.47	77-79%	\$ 3.09-\$3.10	\$ 2.66	16-17%
Specified Items:						
Insurance Settlements ⁽²⁾	—	—		(0.04)	—	
In-Process Research and Development Charge ⁽³⁾	—	—		0.21	—	
Tax Examinations ⁽⁴⁾	—	—		—	(0.04)	
Tax Rate Impact ⁽⁵⁾	—	0.02		—	—	
Repatriation Tax Charge ⁽⁶⁾	—	0.27		—	0.27	
Rounding	—	—		—	(0.01)	
	—	0.29		0.17	0.22	
Diluted EPS from Continuing Operations Excluding Specified Items:⁽¹⁾	\$ 0.83-\$0.84	\$ 0.76	9-11%	\$ 3.26-\$3.27	\$ 2.88	13-14%

(1) Includes the effect on estimated diluted earnings per share from continuing operations of a 3 cent reduction in the fourth quarter and a 6 cent reduction in the twelve-month period ended September 30, 2006 relating to GeneOhm operations, which were acquired in February 2006.

(2) Represents the effect on estimated diluted earnings per share from continuing operations related to proceeds received from insurance settlements regarding the Company's previously owned latex glove business.

(3) Represents the effect on estimated diluted earnings per share from continuing operations of the in-process research and development charge recorded in the second quarter of fiscal 2006 related to the GeneOhm acquisition.

- (4) Represents the effect on diluted earnings per share from continuing operations of the reversal of tax reserves in the first fiscal quarter of 2005 in connection with the conclusion of tax examinations in four non-U.S. jurisdictions.
- (5) Represents the effect on diluted earnings per share from continuing operations of tax-related events that caused the quarterly tax rate to vary from the then-expected effective tax rate for fiscal year 2005.
- (6) Included in diluted earnings per share from continuing operations for the fourth quarter of fiscal 2005 is 27 cents per diluted share substantially related to the impact on taxes of the planned repatriation of \$1.3 billion of foreign earnings under the provisions of the American Jobs Creation Act.

As illustrated in Table 2, the Company estimates that diluted earnings per share from continuing operations will increase approximately 9 to 11 percent for the fourth fiscal quarter of 2006 over diluted earnings per share from continuing operations, excluding specified items, of 76 cents for the fourth fiscal quarter of 2005.

For the full fiscal year 2006, the Company estimates that diluted earnings per share from continuing operations, excluding specified items, are expected to be in the \$3.26 to \$3.27 range, representing an increase of approximately 13 to 14 percent over diluted earnings per share from continuing operations, excluding specified items, of \$2.88 for the fiscal year 2005.

Conference Call Information

A conference call regarding BD's third fiscal quarter results and its expectations for the fourth fiscal quarter and full fiscal year will be broadcast live on BD's website, www.bd.com/investors, at 10:00 a.m. (ET) Friday, July 28, 2006. The conference call will be available for replay through the close of business on August 4, 2006 on BD's website, www.bd.com/investors, or at 1-888-203-1112 (domestic) and 1-719-457-0820 (international), pass code 4856925.

This news release contains certain non-GAAP financial measures. A reconciliation of these and other measures to the comparable GAAP measures is included in this release and in the attached financial tables.

About BD

BD, a leading global medical technology company that makes and sells medical devices, instrumented systems and reagents, is dedicated to improving people's health throughout the world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines. The Company's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs more than 25,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. For more information, please visit www.bd.com.

This press release, including the section entitled "Fiscal 2006 Outlook for Fourth Quarter and Full Year," contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues, earnings per share and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, factors that could cause actual results to vary materially from any forward-looking statement

include, but are not limited to: competitive factors; pricing and market share pressures; changes in interest or foreign currency exchange rates; difficulties inherent in product development and delays in product introductions; changes in regional, national or foreign economic conditions; further increases in energy costs and their effect on, among other things, the cost of producing BD's products; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; uncertainties of litigation (as described in BD's filings with the Securities and Exchange Commission); the effects of potential pandemic diseases; changes in healthcare or other governmental regulation; and issuance of new or revised accounting standards, as well as other factors discussed in this press release and in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per-share data)

	2006	Three Months Ended June 30, 2005	%Change
REVENUES	\$ 1,483,698	\$ 1,381,306	7.4
Cost of products sold	732,943	686,764	6.7
Selling and administrative	393,782	365,919	7.6
Research and development	77,967	67,003	16.4
TOTAL OPERATING COSTS AND EXPENSES	1,204,692	1,119,686	7.6
OPERATING INCOME	279,006	261,620	6.6
Interest expense	(15,425)	(13,695)	12.6
Interest income	12,146	10,134	19.9
Other expense, net	(2,386)	(984)	NM
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	273,341	257,075	6.3
Income tax provision	66,968	67,274	(0.5)
INCOME FROM CONTINUING OPERATIONS	206,373	189,801	8.7
LOSS FROM DISCONTINUED OPERATIONS NET OF INCOME TAX BENEFIT OF \$91 IN 2005	—	(133)	NM
NET INCOME	\$ 206,373	\$ 189,668	8.8
EARNINGS PER SHARE			
Basic:			
Income from continuing operations	\$ 0.84	\$ 0.75	12.0
Loss from discontinued operations	\$ —	\$ —	—
Net income	\$ 0.84	\$ 0.75	12.0
Diluted:			
Income from continuing operations	\$ 0.81	\$ 0.73	11.0
Loss from discontinued operations	\$ —	\$ —	—
Net income	\$ 0.81	\$ 0.73	11.0
AVERAGE SHARES OUTSTANDING			
Basic	246,633	251,866	
Diluted	255,070	260,099	

NM - Not Meaningful

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL INFORMATION
Three Months Ended June 30,
(Unaudited; Amounts in thousands, except per-share data)

	2005		
	As Reported	Tax Rate Impact (1)	Excluding Items
Income taxes	67,274	(2,059)	65,215
effective tax rate	26.2%		25.4%
Income from continuing operations	189,801	2,059	191,860
as a % of revenues	13.7%		13.9%
<u>Diluted earnings per share</u>			
Income from continuing operations	\$ 0.73	\$ 0.01	\$ 0.74

(1) Represents the effect on diluted earnings per share from continuing operations of tax-related events that caused the quarterly tax rate to vary from the then expected effective tax rate for fiscal year 2005.

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per-share data)

	2006	Nine Months Ended June 30, 2005	%Change
REVENUES	\$ 4,347,076	\$ 4,035,205	7.7
Cost of products sold	2,119,320	1,999,283	6.0
Selling and administrative	1,131,434	1,073,346	5.4
Research and development	276,391 (1)	195,074	41.7
TOTAL OPERATING COSTS AND EXPENSES	3,527,145	3,267,703	7.9
OPERATING INCOME	819,931	767,502	6.8
Interest expense	(51,990)	(41,066)	26.6
Interest income	43,808	23,827	83.9
Other expense, net	(3,999)	(6,087)	(34.3)
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	807,750	744,176	8.5
Income tax provision	227,279	173,468	31.0
INCOME FROM CONTINUING OPERATIONS	580,471	570,708	1.7
(LOSS) INCOME FROM DISCONTINUED OPERATIONS NET OF INCOME TAX (BENEFIT) PROVISION OF \$(1,330) AND \$1,547, RESPECTIVELY	(2,170) (2)	2,461	NM
NET INCOME	\$ 578,301	\$ 573,169	0.9
EARNINGS PER SHARE			
Basic:			
Income from continuing operations	\$ 2.34	\$ 2.26	3.5
(Loss) income from discontinued operations	\$ (0.01)	\$ 0.01	NM
Net income (3)	\$ 2.34	\$ 2.27	3.1
Diluted:			
Income from continuing operations	\$ 2.26	\$ 2.18	3.7
(Loss) income from discontinued operations	\$ (0.01)	\$ 0.01	NM
Net income	\$ 2.25	\$ 2.19	2.7
AVERAGE SHARES OUTSTANDING			
Basic	247,588	252,167	
Diluted	256,500	261,897	

NM - Not Meaningful

- (1) Includes the in-process research and development ("IPR&D") charge related to the GeneOhm acquisition.
- (2) Represents certain adjustments relating to the divestiture of Clontech.
- (3) Total per share amounts may not add due to rounding.

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL INFORMATION
Nine Months Ended June 30,
(Unaudited; Amounts in thousands, except per-share data)

	2006			
	As Reported	Insurance Settlement (1)	GeneOhm R&D (2)	Excluding Items
Selling and administrative as a % of revenues	1,131,434 26.0%	17,000	—	1,148,434 26.4%
Research and development as a % of revenues	276,391 6.4%	—	(53,300)	223,091 5.1%
Operating Income as a % of revenues	819,931 18.9%	(17,000)	53,300	856,231 19.7%
Income taxes effective tax rate	227,279 28.1%	(6,460)	—	220,819 26.2%
Income from continuing operations as a % of revenues	580,471 13.4%	(10,540)	53,300	623,231 14.3%
<u>Diluted earnings per share</u>				
Income from continuing operations	\$ 2.26	\$ (0.04)	0.21	\$ 2.43

(1) Represents the effect in 2006 related to proceeds received from insurance settlements in connection with the Company's previously owned latex glove business.

(2) Represents the in-process research and development ("IPR&D") charge related to the GeneOhm acquisition.

	2005			
	As Reported	Tax Examinations (3)	Tax Rate Impact (4)	Excluding Charges
Income taxes effective tax rate	173,468 23.3%	11,265	4,181	188,914 25.4%
Income from continuing operations as a % of revenues	570,708 14.1%	(11,265)	(4,181)	555,262 13.8%
<u>Diluted earnings per share</u>				
Income from continuing operations	\$ 2.18	\$ (0.04)	\$ (0.02)	\$ 2.12

(3) Relates to the reversal of tax reserves in the first quarter 2005 in connection with the conclusion of tax examinations in four non-U.S. jurisdictions.

(4) Represents the effect on diluted earnings per share from continuing operations of tax-related events that caused the quarterly tax rate to vary from the then expected effective tax rate for fiscal year 2005.

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY SEGMENT AND GEOGRAPHIC AREA
(Unaudited; Amounts in thousands)

	2006	Three Months Ended June 30, 2005	% Change
<u>BD MEDICAL</u>			
United States	\$ 383,030	\$ 338,238	13.2
International	445,439	431,980	3.1
TOTAL	\$ 828,469	\$ 770,218	7.6
<u>BD DIAGNOSTICS</u>			
United States	\$ 237,817	\$ 218,536	8.8
International	198,596	192,207	3.3
TOTAL	\$ 436,413	\$ 410,743	6.2
<u>BD BIOSCIENCES</u>			
United States	\$ 98,158	\$ 92,809	5.8
International	120,658	107,536	12.2
TOTAL	\$ 218,816	\$ 200,345	9.2
<u>TOTAL REVENUES</u>			
United States	\$ 719,005	\$ 649,583	10.7
International	764,693	731,723	4.5
TOTAL	\$ 1,483,698	\$ 1,381,306	7.4

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY SEGMENT AND GEOGRAPHIC AREA
(Unaudited; Amounts in thousands)

	2006	Nine Months Ended June 30, 2005	% Change
BD MEDICAL			
United States	\$ 1,122,928	\$ 997,936	12.5
International	1,271,578	1,197,769	6.2
TOTAL	\$ 2,394,506	\$ 2,195,705	9.1
BD DIAGNOSTICS			
United States	\$ 699,818	\$ 650,419	7.6
International	614,529	603,876	1.8
TOTAL	\$ 1,314,347	\$ 1,254,295	4.8
BD BIOSCIENCES			
United States	\$ 278,788	\$ 255,453	9.1
International	359,435	329,752	9.0
TOTAL	\$ 638,223	\$ 585,205	9.1
TOTAL REVENUES			
United States	\$ 2,101,534	\$ 1,903,808	10.4
International	2,245,542	2,131,397	5.4
TOTAL	\$ 4,347,076	\$ 4,035,205	7.7

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended June 30,
(Unaudited; Amounts in thousands)

	United States		
	2006	2005	% Change
BD MEDICAL			
Medical Surgical Systems	\$ 230,123	\$ 208,818	10.2
Diabetes Care	112,432	97,006	15.9
Pharmaceutical Systems	34,612	27,034	28.0
Ophthalmic Systems	5,863	5,380	9.0
TOTAL	\$ 383,030	\$ 338,238	13.2
BD DIAGNOSTICS			
Preanalytical Systems	\$ 131,909	\$ 120,283	9.7
Diagnostic Systems	105,908	98,253	7.8
TOTAL	\$ 237,817	\$ 218,536	8.8
BD BIOSCIENCES			
Discovery Labware	\$ 31,276	\$ 29,374	6.5
Immunocytometry Systems	47,027	43,908	7.1
Pharmingen	19,855	19,527	1.7
TOTAL	\$ 98,158	\$ 92,809	5.8
TOTAL UNITED STATES	\$ 719,005	\$ 649,583	10.7

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended June 30, (continued)
(Unaudited; Amounts in thousands)

	International				
	2006	2005	% Change		
			Reported	FX Neutral	FX Impact
BD MEDICAL					
Medical Surgical Systems	\$ 217,993	\$ 211,676	3.0	2.5	0.5
Diabetes Care	77,660	74,309	4.5	5.3	(0.8)
Pharmaceutical Systems	139,468	136,003	2.5	5.8	(3.3)
Ophthalmic Systems	10,318	9,992	3.3	6.0	(2.7)
TOTAL	\$ 445,439	\$ 431,980	3.1	4.1	(1.0)
BD DIAGNOSTICS					
Preanalytical Systems	\$ 107,589	\$ 102,543	4.9	5.7	(0.8)
Diagnostic Systems	91,007	89,664	1.5	3.1	(1.6)
TOTAL	\$ 198,596	\$ 192,207	3.3	4.5	(1.2)
BD BIOSCIENCES					
Discovery Labware	\$ 24,271	\$ 23,716	2.3	4.6	(2.3)
Immunocytometry Systems	76,947	66,945	14.9	16.6	(1.7)
Pharming	19,440	16,875	15.2	17.7	(2.5)
TOTAL	\$ 120,658	\$ 107,536	12.2	14.1	(1.9)
TOTAL INTERNATIONAL	\$ 764,693	\$ 731,723	4.5	5.7	(1.2)

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended June 30, (continued)
(Unaudited; Amounts in thousands)

	Total				
	2006	2005	% Change		
			Reported	FX Neutral	FX Impact
BD MEDICAL					
Medical Surgical Systems	\$ 448,116	\$ 420,494	6.6	6.3	0.3
Diabetes Care	190,092	171,315	11.0	11.3	(0.3)
Pharmaceutical Systems	174,080	163,037	6.8	9.5	(2.7)
Ophthalmic Systems	16,181	15,372	5.3	7.1	(1.8)
TOTAL	\$ 828,469	\$ 770,218	7.6	8.1	(0.5)
BD DIAGNOSTICS					
Preanalytical Systems	\$ 239,498	\$ 222,826	7.5	7.8	(0.3)
Diagnostic Systems	196,915	187,917	4.8	5.5	(0.7)
TOTAL	\$ 436,413	\$ 410,743	6.2	6.8	(0.6)
BD BIOSCIENCES					
Discovery Labware	\$ 55,547	\$ 53,090	4.6	5.6	(1.0)
Immunocytometry Systems	123,974	110,853	11.8	12.8	(1.0)
Pharming	39,295	36,402	7.9	9.1	(1.2)
TOTAL	\$ 218,816	\$ 200,345	9.2	10.3	(1.1)
TOTAL REVENUES	\$ 1,483,698	\$ 1,381,306	7.4	8.0	(0.6)

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Nine Months Ended June 30,
(Unaudited; Amounts in thousands)

	United States		
	2006	2005	% Change
BD MEDICAL			
Medical Surgical Systems	\$ 672,438	\$ 627,995	7.1
Diabetes Care	338,558	279,949	20.9
Pharmaceutical Systems	95,040	73,855	28.7
Ophthalmic Systems	16,892	16,137	4.7
TOTAL	\$ 1,122,928	\$ 997,936	12.5
BD DIAGNOSTICS			
Preanalytical Systems	\$ 380,110	\$ 342,096	11.1
Diagnostic Systems	319,708	308,323	3.7
TOTAL	\$ 699,818	\$ 650,419	7.6
BD BIOSCIENCES			
Discovery Labware	\$ 87,738	\$ 80,157	9.5
Immunocytometry Systems	133,691	119,653	11.7
Pharmingen	57,359	55,643	3.1
TOTAL	\$ 278,788	\$ 255,453	9.1
TOTAL UNITED STATES	\$ 2,101,534	\$ 1,903,808	10.4

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Nine Months Ended June 30, (continued)
(Unaudited; Amounts in thousands)

	International				
	2006	2005	% Change		
			Reported	FX Neutral	FX Impact
BD MEDICAL					
Medical Surgical Systems	\$ 628,421	\$ 604,355	4.0	4.1	(0.1)
Diabetes Care	223,524	212,240	5.3	7.6	(2.3)
Pharmaceutical Systems	389,912	352,638	10.6	16.9	(6.3)
Ophthalmic Systems	29,721	28,536	4.2	9.0	(4.8)
TOTAL	\$ 1,271,578	\$ 1,197,769	6.2	8.6	(2.4)
BD DIAGNOSTICS					
Preanalytical Systems	\$ 308,413	\$ 294,086	4.9	7.1	(2.2)
Diagnostic Systems	306,116	309,790	(1.2)	2.4	(3.6)
TOTAL	\$ 614,529	\$ 603,876	1.8	4.7	(2.9)
BD BIOSCIENCES					
Discovery Labware	\$ 72,247	\$ 72,307	(0.1)	4.0	(4.1)
Immunocytometry Systems	226,709	205,060	10.6	14.4	(3.8)
Pharming	60,479	52,385	15.5	20.3	(4.8)
TOTAL	\$ 359,435	\$ 329,752	9.0	13.1	(4.1)
TOTAL INTERNATIONAL	\$ 2,245,542	\$ 2,131,397	5.4	8.2	(2.8)

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Nine Months Ended June 30, (continued)
(Unaudited; Amounts in thousands)

	Total				
	2006	2005	% Change		
			Reported	FX Neutral	FX Impact
BD MEDICAL					
Medical Surgical Systems	\$ 1,300,859	\$ 1,232,350	5.6	5.6	—
Diabetes Care	562,082	492,189	14.2	15.2	(1.0)
Pharmaceutical Systems	484,952	426,493	13.7	18.9	(5.2)
Ophthalmic Systems	46,613	44,673	4.3	7.4	(3.1)
TOTAL	\$ 2,394,506	\$ 2,195,705	9.1	10.4	(1.3)
BD DIAGNOSTICS					
Preanalytical Systems	\$ 688,523	\$ 636,182	8.2	9.3	(1.1)
Diagnostic Systems	625,824	618,113	1.2	3.0	(1.8)
TOTAL	\$ 1,314,347	\$ 1,254,295	4.8	6.2	(1.4)
BD BIOSCIENCES					
Discovery Labware	\$ 159,985	\$ 152,464	4.9	6.9	(2.0)
Immunocytometry Systems	360,400	324,713	11.0	13.4	(2.4)
Pharmingen	117,838	108,028	9.1	11.4	(2.3)
TOTAL	\$ 638,223	\$ 585,205	9.1	11.3	(2.2)
TOTAL REVENUES	\$ 4,347,076	\$ 4,035,205	7.7	9.2	(1.5)